Johanna Mylet - Nov 1, 2021 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role
Chief Financial Officer
Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Stock symbol
PSTX
Transactions as of
Nov 1, 2021
Transactions value $
$0
Form type
4
Date filed
11/2/2021, 07:31 PM
Next filing
Dec 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding PSTX Common Stock 28.5K Nov 1, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Employee Stock Option (Right to Buy) Award $0 +65K $0.00 65K Nov 1, 2021 Common Stock 65K $6.53 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,702 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on September 20, 2021.
F2 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter.